Pasar al contenido principal

ESTUDIO DEL MECANISMO DE ACCION DE UN APTAMERO FRENTE A LA PROTEINA QUINASA MNK1 COMO FARMACO ANTITUMORAL EN CANCER DE MAMA

PID2019-105417RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO RAMON Y CAJAL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An optimized MNK1b aptamer, apMNKQ2, and its potential use as a therapeutic agent in breast cancer

  • Pinto-Díez, C.
  • Ferreras-Martín, R.
  • Carrión-Marchante, R.
  • Klett-Mingo, J.I.
  • García-Hernández, Mar
  • Pérez-Morgado, M.I.
  • Sacristán, S.
  • Barragán, M.
  • Seijo-Vila, M.
  • Tundidor, I.
  • Blasco-Benito, S.
  • Pérez-Gómez, E.
  • Gómez-Pinto, Irene
  • Sánchez, C.
  • González, Carlos
  • González, V.M.
  • Martín, M. E.
16 pags., 8 figs., Breast cancer is the most commonly diagnosed and leading cause of cancer death among women worldwide. Mitogen-activated protein kinase-interacting kinases (MNKs) promote the expression of several oncogenic proteins and are overexpressed in several types of cancer. In human cells, there are four isoforms of MNKs. The truncated isoform MNK1b, first described in our laboratory, has a higher basal activity and is constitutively active. Aptamers are emerging in recent years as potential therapeutic agents that show significant advantages over drugs of other nature. We have previously obtained and characterized a highly specific aptamer against MNK1b, named apMNK2F, with a dissociation constant in the nanomolar range, which produces significant inhibition of proliferation, migration, and colony formation in breast cancer cells. Furthermore, its sequence analysis predicted two G-quadruplex structures. In this work, we show the optimization process of the aptamer to reduce its size, improving its stability. The obtained aptamer, named apMNKQ2, is able to inhibit proliferation, colony formation, migration, and invasion in breast cancer cells. In murine models of breast cancer, apMNKQ2 has demonstrated its efficacy in reducing tumor volume and the number of metastases. In conclusion, apMNKQ2 could be used as an anti-tumor drug in the future., C.P.-D. was supported by grant RTC-2014-1986-1 from the Ministry of Economy and Competitiveness (Spain). R.F.-M... by predoctoral contract (PEJD-2018-BMD-4416) from the Community of Madrid (Spain) and FPU19/02929 from the Ministry of Science, Innovation and Universities (Spain). R.C.-B. for predoctoral contracts (PEJD 2016-BMD-2145 and 2018-BMD-9201) from the Community of Madrid and grant RTC2019-07227-1. M. EM., and V.M.G. are researchers at FIBio-HRC. Supported by grants RTC2019-07227-1, PID2020-116620GB-T.I.00, and PID2019-105417RB-I00, funded by MCIN/ AEI /10.13039/501100011033 (Ministry of Economy and Competitiveness, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dependence of Induced Biological Damage on the Energy Distribution and Intensity of Clinical Intra-Operative Radiotherapy Electron Beams

  • Colmenares, R.
  • Carrión-Marchante, Rebeca
  • Martín, M. Elena
  • Salinas Muñoz, Laura
  • García-Bermejo, María Laura
  • Oller, Juan C.
  • Muñoz, Antonio
  • Blanco, Francisco
  • Rosado, Jaime
  • Lozano, Ana I.
  • Álvarez, Sofía
  • García-Vicente, Feliciano
  • García, Gustavo
The survival fraction of epithelial HaCaT cells was analysed to assess the biological damage caused by intraoperative radiotherapy electron beams with varying energy spectra and intensities. These conditions were achieved by irradiating the cells at different depths in water using nominal 6 MeV electron beams while consistently delivering a dose of 5 Gy to the cell layer. Furthermore, a Monte Carlo simulation of the entire irradiation procedure was performed to evaluate the molecular damage in terms of molecular dissociations induced by the radiation. A significant agreement was found between the molecular damage predicted by the simulation and the damage derived from the analysis of the survival fraction. In both cases, a linear relationship was evident, indicating a clear tendency for increased damage as the averaged incident electron energy and intensity decreased for a constant absorbed dose, lowering the dose rate. This trend suggests that the radiation may have a more pronounced impact on surrounding healthy tissues than initially anticipated. However, it is crucial to conduct additional experiments with different target geometries to confirm this tendency and quantify the extent of this effect., This study has partially been supported by the Spanish Ministry of Science and Innovation (Project PID2019-104727RB-C21/C22), Project PID2019-104727RB-C21/C22 to R.C-M, PID2019-105417RB-I00 funded by MCIN/AEI/10.13039/501100011033 (Ministry of Economy and Competitiveness, Spain), to M.E.M and PI21/01822, funded by Instituto de Salud Carlos III and co-funded by the European Regional Development Fund (ERDF, “A way to make Europe”), to M.L.G.-B., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An Aptamer against MNK1 for Non-Small Cell Lung Cancer Treatment

  • Carrión-Marchante, Rebeca
  • Pinto-Díez, Celia
  • Klett-Mingo, José Ignacio
  • Palacios, Esther
  • Barragán-Usero, Miriam
  • Pérez-Morgado, M. Isabel
  • Pascual-Mellado, Manuel
  • Alcalá, Sonia
  • Ruiz-Cañas, Laura
  • Sainz, Bruno Jr.
  • González, Víctor M.
  • Martín, M. Elena
Lung cancer is the leading cause of cancer-related death worldwide. Its late diagnosis and consequently poor survival make necessary the search for new therapeutic targets. The mitogen-activated protein kinase (MAPK)-interacting kinase 1 (MNK1) is overexpressed in lung cancer and correlates with poor overall survival in non-small cell lung cancer (NSCLC) patients. The previously identified and optimized aptamer from our laboratory against MNK1, apMNKQ2, showed promising results as an antitumor drug in breast cancer in vitro and in vivo. Thus, the present study shows the antitumor potential of apMNKQ2 in another type of cancer where MNK1 plays a significant role, such as NSCLC. The effect of apMNKQ2 in lung cancer was studied with viability, toxicity, clonogenic, migration, invasion, and in vivo efficacy assays. Our results show that apMNKQ2 arrests the cell cycle and reduces viability, colony formation, migration, invasion, and epithelial-mesenchymal transition (EMT) processes in NSCLC cells. In addition, apMNKQ2 reduces tumor growth in an A549-cell line NSCLC xenograft model. In summary, targeting MNK1 with a specific aptamer may provide an innovative strategy for lung cancer treatment., R.C.-M. was supported for predoctoral contracts (PEJD 2016-BMD-2145 and 2018-BMD-9201) from the Community of Madrid and grant RTC2019-07227-1. M.E.M. and V.M.G. are researchers from FIBio-HRC supported by Consejeria de Sanidad (CAM). This work was supported by grants RTC2019-07227-1 and PID2019-105417RB-I00, funded by MCIN/AEI/10.13039/501100011033 (Ministry of Economy and Competitiveness, Spain)., Peer reviewed